Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Saxena White P.A. Files Securities Fraud Class Action Against Delcath Systems, Inc.


Saxena White P.A. Files Securities Fraud Class Action Against Delcath Systems, Inc.

BOCA RATON, FL -- (Marketwired) -- 06/17/13 -- Saxena White P.A. has filed a securities fraud class action lawsuit in the United States District Court for the Southern District of New York against Delcath Systems, Inc. ("Delcath" or the "Company") (NASDAQ: DCTH) and certain of the Company's executive officers. The class action is filed on behalf of investors who purchased or otherwise acquired Declath's common stock during the period from April 21, 2010 and May 2, 2013, inclusive (the "Class Period"). The complaint brings claims for violations of the Securities Exchange Act of 1934.

Delcath operates as a specialty pharmaceutical and medical device company focusing on the field of oncology. The Company's proprietary technology purportedly enables the administration of high-dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company's New Drug Application ("NDA") for its Melblez Kit (consists of a drug (melphalan) and a device bundled together in a single package) for the treatment of patients with unresectable ocular melanoma metastatic to the liver contained risks including substantial and severe toxicity and deaths associated with the drug's adverse reactions; and (2) the Company's manufacturing facilities were in violation of Current Good Manufacturing Practices.

You may obtain a copy of the complaint and join the class action at www.saxenawhite.com. If you purchased Delcath stock between April 21, 2010 and May 2, 2013, inclusive, you may contact Joe White (jwhite@saxenawhite.com) or Marc Grobler (mgrobler@saxenawhite.com) at Saxena White P.A. to discuss your rights and interests.

If you purchased Delcath common stock during the Class Period of April 21, 2010 through May 2, 2013, and wish to apply to be the lead plaintiff in this action, a motion on your behalf must be filed with the Court no later than July 8, 2013. You may contact Saxena White P.A. to discuss your rights regarding the appointment of lead plaintiff and your interest in the class action. Please note that you may also retain counsel of your choice and need not take any action at this time to be a class member.

Saxena White P.A., located in Boca Raton, specializes in prosecuting securities fraud and complex class actions on behalf of institutions and individuals. Currently serving as lead counsel in numerous securities fraud class actions nationwide, the firm has recovered hundreds of millions of dollars on behalf of injured investors and is active in major litigation pending in federal and state courts throughout the United States.

Joseph E. White, III jwhite@saxenawhite.com

Marc Grobler mgrobler@saxenawhite.com

Saxena White P.A. 2424 North Federal Highway, Suite 257 Boca Raton, FL 33431 Tel: (561) 394-3399 Fax: (561) 394-3382 www.saxenawhite.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement